药捷安康-B(02617.HK)发表核心产品替恩戈替尼针对胆管癌的探索性临床结果

Core Insights - The core product of the company, Tiengotine, has shown promising results in a Phase 2 exploratory clinical trial for cholangiocarcinoma published in The Lancet Gastroenterology & Hepatology [1] Company Summary - Tiengotine is designed to overcome acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma, demonstrating anti-tumor activity in patients with other FGFR gene alterations and FGFR wild-type patients [1]